SGLT2 Inhibitors, like Invokana, Found to Double Risk of Diabetic Ketoacidosis

June 08, 2017 - pharmaceutical

Doctors find certain diabetes drugs can increase the chance for potentially fatal acidic blood condition.

In a June 8, 2017 correspondence to the New England Journal of Medicine, doctors associated with Harvard Medical School wrote that SGLT2 inhibitors, a class of type 2 diabetes drugs that includes Invokana and Invokamet, can double the risk of diabetic ketoacidosis when compared to DPP4 inhibitors, a different kind of diabetes drug.

The researchers identified patients who had recently started treatment of their diabetes with either an SGLT2 inhibitor or a DPP4 inhibitor. In assessing over 140,000 diabetes patients who had begun treatment using either drug, the researchers found that those taking SGLT2 inhibitors, like Invokana, Invokamet, or other gliflozins, suffered diabetic ketoacidosis at nearly twice the rate of those taking DPP4 inhibitors. Diabetic ketoacidosis is a medical condition where the body, lacking insulin, breaks down fat for energy, causing the release of ketones into the bloodstream. The release of ketones causes the blood to become acidic, resulting in weakness, fatigue, nausea, excessive thirst, frequent urination and vomiting. Untreated diabetic ketoacidosis can be fatal.

Invokana and Ketoacidosis

Dr. Fralick, a general internist and a researcher on the study told Medscape Medical News that he still supports the use of SGLT2 inhibitors, but that “it’s important right after patients are started on these drugs that they’re closely monitored,” due to the increased risk of diabetic ketoacidosis. To assess the risks in taking SGLT2 inhibitors, Fralick and his colleagues used a healthcare insurance claims database to identify patients taking the drugs and what outcomes they experienced. The researchers plan to use the same database to further investigate the claim that Invokana-like drugs cause an increased risk of requiring leg or foot amputations. The finding of increased amputation risk recently resulted in the U.S. Food & Drug Administration issuing a warning and requiring the manufacturers to display the risk of amputation on the box of the drug.

Johnson & Johnson’s Invokana remains the subject of many lawsuits filed by patients who have taken the drug. Patients claim that had they known about the risks of amputation and diabetic ketoacidosis earlier, they may have chosen a different treatment option for their type 2 diabetes. Many of these lawsuits have been consolidated into ongoing multidistrict litigation.


Free Case Evaluation

Get in touch with our lawyers for a free and confidential case review by calling us toll free at 1 (888) 402-5552 or by filling out the form below.

DISCLAIMER: No attorney client relationship will exist between you and our firm until we enter into a signed Retainer/Services Agreement. Completion of this document is for informational purposes only and does not constitute a Retainer/Services Agreement. The information you obtain at this site is not, nor is it intended to be, legal advice. Contacting us does not create an attorney-client relationship. In some jurisdictions this website may be considered lawyer advertising. You should consult an attorney for advice regarding your individual situation. Click here for more information.


Back To More Articles